AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is struggling to gain traction with investors, as evidenced by its 3.59 million shares volume. The daily trading volume average remained 3.09 million shares over the course of 3 months. The stock had opened the regular trading at $3.65 and managed a 10.14% price change to reach $3.91 through the close.AcelRx Pharmaceuticals, Inc. (ACRX) Analyst Opinion
AcelRx Pharmaceuticals, Inc. is currently rated as outperform by 8 stock analysts, with the company still having around 17.1% shares outstanding that can be sold short legally. The value of their shares went up by 47.55% last month. Over the course of a year, the stock has grown by 93.09%. Financial analysts are becoming more bullish than ever, with the 6 analysts who cover the activities of ACRX advising investors to buy. Experts on Wall Street have set a price target of $8.33 for the stock. The decision was arrived after looking at their 113.04% gain from current levels. At the moment, AcelRx Pharmaceuticals, Inc. (ACRX) trading price is around -22.57% below its 52-week high.
AcelRx Pharmaceuticals, Inc. (ACRX) was unsuccessful in overcoming the expected -$0.21 as the stock recorded an earnings of -$2.10E-01 a piece during their last financial report presentation. Revenue, meanwhile, had a distance of 10.98% from the previous quarter, with the company recording $910000 in revenue.AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Intraday View
The shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have struggled and recovered 136.97% ever since it recorded its 52 week low. During the course of 5 days, the stock price volatility has remained at 17.73%, increasing the time frame to a month, the volatility recorded was 16.55%. The price of their shares still hasn’t been successful in staying above its 20 days moving average, staying at a distance of -2.98% and while its 50 moving average is around 6.39%. A look at previous five trading sessionACRX stock had returned -5.78% and has spiked 33.87% when compared to its 200-day moving average that is $3.32. AcelRx Pharmaceuticals, Inc. (ACRX) will look to keep its 105.79% increase that it witnessed in the past one year.
As the normal trading session ended, the stock of Manulife Financial Corporation (NYSE:MFC), fetched in a $0.62 spike to $16.98. The session began with the stock price at $16.62, hitting a high of $16.65 before down again. For the week, analysts seem to be okay with their bullish with the consensus call staying at 1.5. Manulife Financial Corporation gets 3 buy analyst recommendations while 2 recommend a hold and 0 rated it as a sell. The shares of the company tumbled -23.38% from its high $22.16, with their overall market value now roughly $33.69 billion.
The mean recommendation of MFC on Reuter’s scale remained unchanged from 2.06 to 2.06 within 30 days. This figure implies that the majority of analysts rate it as a buy. The price target for Manulife Financial Corporation (NYSE:MFC) is now around $23.61 a share, implying the stock has what it takes to grow by 39.05%. The recent trading session also indicated the stock needs to add 75.21% more meet analysts’ high consensus price target.
The current trading volume of the company was 3.05 million shares during the last session. That compares with the recent average volume of 3.08 million shares. By the end of the regular trading session, the price volatility over a 1-week span was 2.93 while month stood 2.75%. The stock price of MFC dropped to $16.25 during the day and at a certain time in 12 months it traded as low as $14.99. It has made a 13.24% recovery since its 52-week low point and has returned -18.6% year-to-date.